StockNews.com Initiates Coverage on DBV Technologies (NASDAQ:DBVT)

StockNews.com started coverage on shares of DBV Technologies (NASDAQ:DBVT) in a report released on Tuesday. The firm issued a hold rating on the stock.

Separately, JMP Securities restated a “market outperform” rating and issued a $10.00 target price on shares of DBV Technologies in a research report on Friday, January 10th.

DBV Technologies Trading Down 5.6 %

Shares of NASDAQ DBVT opened at $7.35 on Tuesday. The company has a market cap of $151.18 million, a price-to-earnings ratio of -1.63 and a beta of -0.08. The stock’s 50 day simple moving average is $5.23 and its 200 day simple moving average is $4.20. DBV Technologies has a 12-month low of $2.20 and a 12-month high of $8.50.

DBV Technologies (NASDAQ:DBVT) last posted its earnings results on Friday, April 11th. The company reported ($1.10) earnings per share (EPS) for the quarter. DBV Technologies had a negative net margin of 815.73% and a negative return on equity of 106.07%. The firm had revenue of $0.51 million for the quarter. As a group, equities analysts forecast that DBV Technologies will post -7.05 earnings per share for the current fiscal year.

Institutional Investors Weigh In On DBV Technologies

A hedge fund recently bought a new stake in DBV Technologies stock. Boxer Capital Management LLC acquired a new position in DBV Technologies S.A. (NASDAQ:DBVT) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund acquired 50,000 shares of the company’s stock, valued at approximately $154,000. Boxer Capital Management LLC owned about 0.24% of DBV Technologies at the end of the most recent reporting period. Hedge funds and other institutional investors own 71.74% of the company’s stock.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.